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SYNTHETIC CELLS, SYNTHETIC LIFE, AND 
INHERITANCE 
Kristine S. Knaplund* 
I.  INTRODUCTION 
“This is the first self-replicating species that we’ve had on the 
planet whose parent is a computer.”1 
In May 2010, J. Craig Venter and his team announced the creation of 
a “synthetic cell,” or as the team described it, a process of “synthesis, 
assembly, cloning, and successful transplantation [of a synthetic 
genome] to create a new cell controlled by this synthetic genome.”2  They 
chose to start with a simple bacterium, Mycoplasma genitalium (“M. 
genitalium”) because it has “the smallest complement of genes of any 
known organism capable of independent growth in the laboratory.”3  
Using chemical enzymes and live bacteria, they were able to replicate the 
genome sequence of M. genitalium and then transplant it into a natural 
cell controlled by the synthetic genome.4  Although the team had not 
created a new cell entirely from chemicals, their research demonstrates 
progress towards that end. 
The creation of a synthetic genome is an important advancement in 
synthetic biology, “an emerging field of research that combines elements 
of biology, engineering, genetics, chemistry, and computer science.”5  
Synthetic biology research often begins with a “[t]op-down” approach, 
using existing genes and other materials as parts to be analyzed or 
possibly reconfigured.6  For Venter’s team, that included sequencing the 
                                                 
* Professor of Law, Pepperdine University School of Law.  The Author wishes to 
acknowledge the outstanding work of her research assistants David Peromsik and Jennifer 
Vagle and research librarian Jennifer Allison, the Dean’s Summer Research Fund, and the 
participants in the Valparaiso Law Review Symposium on Bioethics, Law and Synthetic 
Biology. 
1 See generally J. Craig Venter Inst., Craig Venter Unveils “Synthetic Life”, TED:  IDEAS 
WORTH SPREADING (May 2010), http://www.ted.com/talks/craig_venter_unveils_ 
synthetic_life.html (announcing the first fully functioning, reproducing cell controlled by 
synthetic DNA). 
2 Daniel G. Gibson et al., Creation of a Bacterial Cell Controlled by a Chemically Synthesized 
Genome, 329 SCI. 52,  55 (2010). 
3 Id. at 52. 
4 Id. at 55–56. 
5 PRESIDENTIAL COMM’N FOR THE STUDY OF BIOETHICAL ISSUES, NEW DIRECTIONS:  THE 
ETHICS OF SYNTHETIC BIOLOGY AND EMERGING TECHNOLOGIES 36 (2010), 
http://www.bioethics.gov/documents/synthetic-biology/PCSBI-Synthetic-Biology-
Report-12.16.10.pdf [hereinafter NEW DIRECTIONS]. 
6 Id. 
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genome of M. genitalium in 1995.7  Synthetic biology also includes 
“[b]ottom-up” research to create new organisms using only chemical 
reagents.8 
Synthetic biology is used today in the field of assisted reproduction 
to analyze existing genes.  An example of such “top-down” synthetic 
biology is preimplantation genetic diagnosis (“PGD”) to screen for 
human immunodeficiency virus, cystic fibrosis, or other diseases.9  This 
Article will focus on the “bottom-up” use of synthetic biology in the 
context of assisted reproduction.  One day, scientists may be able to 
create synthetic human gametes or embryos for purposes of assisted 
reproduction.10  It is impossible to forecast when this may occur; as the 
2010 Presidential Commission for the Study of Bioethical Issues noted, 
“the pace of discovery is unpredictable.”11  But instead of deferring the 
discussion until synthetic sperm or ova actually appear, we should 
anticipate the risks and benefits now.  This Article will focus on the 
practical and regulatory issues that may encourage or inhibit the use of 
Venter’s technology to create synthetic gametes and the legal issues of 
parentage and inheritance for a synthetically created child. 
Part II of this Article sets the stage by briefly discussing infertility in 
the United States, the development of assisted reproduction technologies 
to counteract infertility, and other additional uses of assisted 
reproductive technologies (“ART”) such as PGD, which is also used by 
fertile couples.  Part III examines the existing laws and regulations that 
may apply to the development of synthetic human gametes or embryos.  
With the market demands from Part II and the regulatory structure from 
Part III in mind, Part IV will look at the parentage and inheritance issues 
if a synthetic gamete results in a living child.  Part V concludes the 
Article by exploring two approaches to regulatory issues. 
This Article will follow Recommendation Fifteen from the 
Presidential Commission regarding Information Accuracy: 
                                                 
7 Gibson et al., supra note 2, at 52. 
8 NEW DIRECTIONS, supra note 5, at 36. 
9 Id. at 66.  Preimplantation genetic diagnosis (“PGD”) is used to screen for certain 
genetic or chromosomal diseases, while preimplantation genetic screening (“PGS”) can be 
used for other purposes, such as genetic characteristics. Jaime King, Predicting Probability:  
Regulating the Future of Preimplantation Genetic Screening, 8 YALE J. HEALTH POL’Y L. & 
ETHICS 283, 284 (2008).  This Article will use the term “PGD” to encompass both concepts. 
10 Already, “new developments in basic science have led to new understandings about 
how to create and manipulate human gametes—only recently, scientists have discovered 
how to create artificial mouse eggs from embryonic stem cells.”  Gail H. Javitt & Kathy 
Hudson, Regulating (for the Benefit of) Future Persons:  A Different Perspective on the FDA’s 
Jurisdiction to Regulate Human Reproductive Cloning, 2003 UTAH L. REV. 1201, 1208. 
11 NEW DIRECTIONS, supra note 5, at 67. 
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When discussing synthetic biology, individuals and 
deliberative forums should strive to employ clear and 
accurate language.  The use of sensationalist buzzwords 
and phrases such as “creating life” or ”playing God” 
may initially increase attention to the underlying science 
and its implications for society, but ultimately such 
words impede ongoing understanding of both the 
scientific and ethical issues at the core of public debates 
on these topics.  To further promote public education 
and discourse, a mechanism should be created, ideally 
overseen by a private organization, to fact-check the 
variety of claims relevant to advances in synthetic 
biology.12 
II.  INFERTILITY AND ASSISTED REPRODUCTION 
The infertility industry in the United States is big business.  A 
Centers for Disease Control and Prevention (“CDC”) report presented 
the latest data on infertility: 
• Of the approximately 62 million women of reproductive 
age in 2002, about 1.2 million, or 2%, had an infertility-
related medical appointment within the previous year 
and an additional 10% had received infertility services at 
some time in their lives.  (Infertility services include 
medical tests to diagnose infertility, medical advice and 
treatments to help a woman become pregnant, and 
services other than routine prenatal care to prevent 
miscarriage.) 
• Additionally, 2.1 million couples or about 7% of married 
couples, in which the woman was of reproductive age 
reported that they had not used contraception for 12 
months and the woman had not become pregnant.13 
Just one aspect of assisted reproduction, the exchange of eggs (ova), 
has been estimated to be worth $4.5 billion in the United States.14  
                                                 
12 Id. at 15. 
13 CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP’T OF HEALTH & HUMAN SERVS., 
2006 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES:  NATIONAL SUMMARY AND 
FERTILITY CLINIC REPORTS 3 (2008), http://www.cdc.gov/ART/ART2006/508PDF/ 
2006ART.pdf [hereinafter 2006 ART SUCCESS RATES] (providing data from the 2002 
National Survey of Family Growth). 
14 Sunni Yuen, Comment, An Information Privacy Approach to Regulating the Middlemen in 
the Lucrative Gametes Market, 29 U. PA. J. INT’L L. 527, 546 (2007). 
Knapland: Synthetic Cells, Synthetic Life, and Inheritance
Produced by The Berkeley Electronic Press, 2011
1364 VALPARAISO UNIVERSITY LAW REVIEW [Vol. 45 
Donated ova are used in about 12% of the assisted reproduction 
procedures reported to the CDC.15 
The first widely available technology for infertility was assisted or 
artificial insemination (“AI”), in which semen is inserted into the 
woman’s cervix or uterus via syringe.  The first report of AI for human 
use was published in 1884, but the technique had been used long before 
in animal husbandry.16 
AI solves only a limited range of fertility problems, prompting 
scientists to work on other methods of assisted reproduction in which 
both the sperm and the egg (ovum) can be handled in the laboratory.  
Worries about possible birth defects, the discarding of gametic material, 
and other issues led to a ban on the use of federal funds for such research 
in 1973, but research funded from non-federal sources and in other 
countries continued.17  Drs. Steptoe and Edwards of the United Kingdom 
radically altered the discussion when they introduced the first “test 
tube” baby in a 1978 press release.18  Similar to Venter’s synthetic 
genome, the success of in vitro fertilization (“IVF”), in which the egg and 
sperm are joined in a Petri dish and later implanted in a woman’s 
uterus,19 was termed the “medical media event of the year” in a Hastings 
Center Report.20  After roughly one hundred attempts, the process ended 
successfully with the birth of Louise Brown.21  Once an apparently 
healthy baby was born, the U.S. Ethics Advisory Board, at the urging of 
Joseph Califano, Secretary of Health, Education, and Welfare,22 
recommended reversing the ban on federal research funds, but otherwise 
left oversight of IVF to the states.23  Since 1978, more than three million 
                                                 
15 2006 ART SUCCESS RATES, supra note 13, at 56. 
16 Carolyn Sappideen, Life After Death—Sperm Banks, Wills and Perpetuities, 53 AUSTL. L. J. 
311, 311 (1979). 
17 Robert Toth, Panel To Consider Ethics of Test-Tube Baby Research, L.A. TIMES, Sept. 15, 
1978, at B1. 
18 1978:  First ‘Test Tube Baby’ Born, BBC:  ON THIS DAY http://news.bbc.co.uk/ 
onthisday/hi/dates/stories/july/25/newsid_2499000/2499411.stm (last visited Apr. 14, 
2011). 
19 See Kerry Lynn Macintosh, Brave New Eugenics:  Regulating Assisted Reproductive 
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 264–65 
(explaining the standard IVF procedure). 
20 Daniel Callahan, In Vitro Fertilization:  Four Commentaries, HASTINGS CTR REP., Oct. 
1978, at 7. 
21 Walter Sullivan, Doctor in Laboratory Conception Says First 100 Attempts Failed, N.Y. 
TIMES, Dec. 1, 1978, at A21. 
22 Robert Toth, Califano Urges Debate on Baby Research, L.A. TIMES, Sept. 16, 1978, at A2. 
23 Dena Kleiman, Anguished Search To Cure Infertility:  Medical Advances Offer New Hope, 
But Infertility Affects More Couples Than Ever, N.Y. TIMES, Dec. 16, 1979, at SM38. 
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babies have been born worldwide using assisted reproduction 
technologies.24 
Cryopreservation, the ability to store sperm, ova, and embryos for 
later use, is widely used today.  The ability to successfully freeze sperm 
has been available for over fifty years.25  However, cryopreservation of 
embryos is more recent and widely available, with 100% of fertility 
clinics reporting to the CDC that they offer this service as part of assisted 
reproduction.26  Freezing unfertilized eggs is now possible, but it is 
considered experimental by the American Society of Reproductive 
Medicine and the American College of Obstetrics and Gynecologists.27 
Sperm and ova can be retrieved after a person’s death or while a 
person is in a persistent vegetative state.  Cappy Rothman first reported 
his method to extract sperm postmortem in 1980.28  Although it is 
possible to retrieve ova after a woman has died, no such instance has 
been reported to date.  A recent article in the New England Journal of 
Medicine considered the ethics of granting a husband’s request to keep 
his wife, who was on life support, alive long enough to retrieve her eggs; 
the request was ultimately denied.29 
Along with ART such as IVF, clinics also offer services evidencing 
“top-down” synthetic biology such as sex selection and PGD.  
Commercial techniques such as MicroSort separate male-producing 
sperm from female-producing sperm.30  The woman is then inseminated 
with sorted sperm of the desired gender.31  PGD involves removing one 
cell from an early-stage embryo and testing that cell either for various 
traits including sex or for genes that cause diseases such as cystic 
fibrosis.32 
                                                 
24 Macintosh, supra note 19, at 259. 
25 Sappideen, supra note 16, at 311. 
26 See 2006 ART SUCCESS RATES, supra note 13, at 89 (finding that 100% of the reporting 
clinics offered cryopreservation of embryos as one of their services). 
27 Judy Foreman, Health Sense:  Success Rate Elusive on Frozen Eggs, L.A. TIMES, Aug. 16, 
2010, at E3. 
28 Cappy Miles Rothman, A Method for Obtaining Viable Sperm in the Postmortem State, 34 
FERTILITY & STERILITY 512, 512 (1980). 
29 David M. Greer et al., Case 21-2010—A Request for Retrieval of Oocytes from A 36-Year-
Old Woman with Anoxic Brain Injury, 363 NEW ENG. J. MED. 276, 279, 282 (2010). 
30 See MicroSort®, GENETICS & IVF INST., http://www.microsort.net (last visited Apr. 3, 
2011) (discussing the Microsort technique, related clinical studies, and eligibility 
requirements for interested parties). 
31 Rob Stein, A Boy for You, a Girl for Me:  Technology Allows Choice, WASH. POST, Dec. 14, 
2004, at A1. 
32 Judy Peres, High Stakes of High-Tech Medicine:  Who Is At Fault When Cutting-Edge 
Technology Fails and Who Must Pay the Price?  A Couple’s Lawsuit Looks at the Issues of Consent 
and Experimentation in Assisted Reproductive Technologies, CHI. TRIB., Nov. 1, 1998, at C1. 
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Current techniques allow ART users to select an embryo with the 
desired characteristics and discard another.  If a synthetic sperm or 
ovum is created, the user could select for a wide range of genetic 
characteristics, even those not present in the intended parents. 
III.  EXISTING REGULATIONS 
If researchers begin using Venter’s techniques to create a synthetic 
gamete, would federal and state regulations encourage or hinder their 
efforts?  Existing laws and regulations on synthetic genomes primarily 
focus on biosafety concerns to ensure that the new creations are not 
released into the wild and that villains are not trying to concoct 
hazardous substances such as anthrax or small pox.  The PATRIOT Act33 
expanded 18 USC § 175 (prohibitions with respect to biological weapons) 
by adding the following subsection: 
 (b) ADDITIONAL OFFENSE.—Whoever knowingly 
possesses any biological agent, toxin, or delivery system 
of a type or in a quantity that, under the circumstances, 
is not reasonably justified by a prophylactic, protective, 
bona fide research, or other peaceful purpose, shall be 
fined under this title, imprisoned not more than 10 
years, or both.  In this subsection, the terms “biological 
agent” and “toxin” do not encompass any biological 
agent or toxin that is in its naturally occurring 
environment, if the biological agent or toxin has not 
been cultivated, collected, or otherwise extracted from 
its natural source.34 
Regulations issued by federal agencies such as the CDC, the 
Department of Agriculture, and the Department of Commerce have 
listed the biological agents, toxins, and so on that would violate the 
PATRIOT Act.35  Vendors synthesizing DNA use screening software 
                                                 
33 Uniting and Strengthening America by Providing Appropriate Tools Required to 
Intercept and Obstruct Terrorism (USA PATRIOT Act) Act of 2001, Pub. L. No. 107-56, 115 
Stat. 272 (codified in scattered sections of the U.S.C.). 
34 18 U.S.C. § 175(b) (2006). 
35 See 7 C.F.R. § 331.3 (2010) (providing the Department of Agriculture’s list of toxins 
and agents capable of producing harm to plants and plant products); 9 C.F.R. § 121.3 (2010) 
(providing the Department of Agriculture’s list of toxins and agents capable of producing 
harm to public health and safety, animals, and animal products); 15 C.F.R. pt. 774 (2010) 
(outlining the relevant sections:  1C351, 1C353, 1C354 and 1C991); 42 C.F.R. § 73.3 (2011) 
(listing the specific agents and toxins considered by the Department of Health and Human 
Services to pose serious risks and dangers to the public). 
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such as “BlackWatch” to test whether the requested DNA sequence is on 
the list of banned agents.36  The list of pathogens tested includes seventy-







Pathogen Type  
Viruses 19 12 2 33 
Bacteria 15 3 8 26 
Fungi 2 0 2 11 
Rickettsiae [parasite 
related] 
4 0 9 4 
Prions [proteins that 
cause degenerative brain 
disease, like mad cow] 
0 1 0 1 
Toxins 22 0 0 22 
 
These current regulations would have little effect on the creation of 
synthetic sperm or ovum; although researchers would need to check 
their DNA sequences against the list of pathogens, it is not their goal to 
create one of them.  A more significant impact on synthetic gamete 
research may be found in the regulations on assisted reproduction, 
which impose limitations on sperm banks, fertility clinics, and other 
providers of infertility services.  How much of an impact these 
regulations would have depends in part on whether creating a synthetic 
gamete is seen as akin to processes such as PGD or more like oocyte 
transfer or cloning.  These questions, in turn, require examination of the 
regulations regarding both gametes and embryos.  Most regulation today 
is focused on controlling communicable diseases, inhibiting the sale of 
genetic material, or avoiding the destruction of embryos.  IVF clinics 
report to the CDC, and states have various regulations incidentally 
affecting IVF, such as bans on the sale of ova or refusals to enforce 
surrogacy contracts.  However, generally speaking, the free market has 
reigned.38  By determining that the procedure used  by Louise Brown’s 
                                                 
36 Robert Jones, Sequence Screening, in WORKING PAPERS FOR SYNTHETIC GENOMICS:  RISKS 
AND BENEFITS FOR SCIENCE AND SOCIETY 1, 2 (MS Garfinkel et al. eds., 2007), available at 
http://www.jcvi.org/cms/fileadmin/site/research/projects/synthetic-genomics-
report/Jones-Sequence-Screening.pdf. 
37 Id. at 10. 
38 See Jaime King, Predicting Probability:  Regulating the Future of Preimplantation Genetic 
Screening, 8 YALE J. HEALTH POL’Y L. & ETHICS 283, 357 (2008) (noting that “a technological 
revolution in reproduction is coming” and suggesting that the time to regulate is now). 
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mother was a treatment for her infertility rather than medical 
experimentation on human subjects, the IVF industry has been allowed 
to develop with little restriction in the United States. 
A. ART/Embryos 
In 2004, the President’s Council on Bioethics observed in its report, 
Reproduction & Responsibility:  The Regulation of New Biotechnologies, that 
new reproductive technologies “move from the experimental context to 
clinical practice with relatively little oversight or 
deliberation. . . . Current professional guidelines dictate only that there 
be two peer-reviewed papers showing an acceptable risk-benefit ratio 
before the status of a new practice is elevated from ‘experimental’ to 
‘clinically acceptable.’”39  PGD and preimplantation genetic screening 
(“PGS”)40 have remained largely unregulated, arguably due to political 
reasons41 and constitutional concerns regarding intrusion upon 
recognized procreative liberties.42  Less controversial experimental 
techniques such as intracytoplasmic sperm injection “have entered 
clinical practice with limited prior testing and limited monitoring of their 
effects on the children produced with their aid.”43  Consequently, ART 
remains largely unregulated by both the federal government and states.44 
                                                 
39 PRESIDENT’S COUNCIL ON BIOETHICS, REPRODUCTION & RESPONSIBILITY:  THE 
REGULATION OF NEW BIOTECHNOLOGIES 176 (2004) [hereinafter 2004 PRESIDENT’S COUNCIL 
REPORT].  Furthermore, “[o]nce in practice, these techniques are used at clinicians’ 
discretion, with little or no external oversight.  Use of effective technologies becomes 
widespread rapidly.”  Id. 
40 See King, supra note 38, at 290–96 (describing the technologies involved in PGS). 
41 Jaime King states that 
[o]ne of the main reasons the United States has not regulated PGS is 
because American politicians do not find it politically advantageous.  
The lack of political interest has occurred for three reasons:  1) few 
studies have demonstrated harm to children from PGS; 2) the current 
technological limitations of PGS have restricted both patient demand 
and the frequency of its use for controversial purposes; and 3) PGS 
regulation is politically divisive.  As a result, politicians have 
effectively tabled the issue until a significant harm or risk demands 
political action. 
Id. at 321. 
42 See id. at 326–29 (discussing the constitutional considerations regarding procreative 
liberties); see also Susannah Baruch, Preimplantation Genetic Diagnosis and Parental 
Preferences:  Beyond Deadly Disease, 8 HOUS. J. HEALTH L. & POL’Y 245, 261–62 (2008) (noting 
that the political and legal challenges on regulating the use of PGD are similar to the 
debates over abortion). 
43 2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 174–75.  Intracytoplasmic sperm 
injection (“ICSI”) is “a procedure in which a single sperm is injected directly into an 
egg . . .”  2006 ART SUCCESS RATES, supra note 13, at APPENDIX B, GLOSSARY OF TERMS]. 
44 See infra Parts III.A.1 and III.A.2 (discussing federal and state regulation of ART). 
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1. Federal Regulation of ARTs 
Currently, there are three significant restrictions at the federal level 
regarding research on embryos and the practice of ART:  (1) the 
reporting requirement administered by the CDC; (2) a ban on federal 
funding for research involving the destruction of human embryos; and 
(3) the regulation of practices such as somatic cell nuclear transfer, 
commonly known as cloning. 
a. The CDC Reporting Requirement 
The Fertility Clinic Success Rate and Certification Act of 1992 
(“FCSRCA”)45 requires each ART program handling ova or embryos to 
report annually to the CDC the “(1) pregnancy success rates achieved by 
such program through each assisted reproductive technology, and (2) the 
identity of each embryo laboratory . . . used by such program and 
whether the laboratory is certified . . . or has applied for such 
certification.”46  The FCSRCA further directs the CDC to annually 
publish, among other information 
pregnancy success rates reported to the [CDC] under 
section 263a-1(a)(1) of this title and, in the case of an 
assisted reproductive technology program which failed 
to report one or more success rates as required under 
such section, the name of each such program and each 
pregnancy success rate which the program failed to 
report.47 
Although the FCSRCA instructs the CDC to “develop a model 
program for the certification of embryo laboratories . . . to be carried out 
by the States,”48 it further provides that “[i]n developing the certification 
program, the [CDC] may not establish any regulation, standard, or 
requirement which has the effect of exercising supervision or control 
over the practice of medicine in assisted reproductive technology 
programs.”49 
                                                 
45 Fertility Clinic Success Rate and Certification Act of 1992, Pub. L. No. 102-493, 106 
Stat. 3146 (codified as amended at 42 U.S.C. §§ 263a-1 to -7 (2006)). 
46 42 U.S.C. § 263a-1(a)(1) to (2).  The Act defines “assisted reproductive technology” as 
techniques handling ova or embryos, and thus excludes sperm banks and assisted 
insemination, in which only the sperm is handled outside the body.  42 U.S.C. § 236a-7(1). 
47 Id. § 263a-5(1)(A). 
48 Id. § 263a-2(a)(1). 
49 Id. § 263a-2(i)(1).  Similarly, the FCSRCA provides that “[i]n adopting the certification 
program, a State may not establish any regulation, standard, or requirement which has the 
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If an ART clinic began using synthetic gametes or embryos, the clinic 
would simply need to include the outcomes of the implantations in its 
statistics.  One question would arise as to which category to place the 
synthetic materials; the current report is broken into two parts:  those 
with “non-donor eggs” and those with “donor eggs.”  There is no 
separate category for “donor sperm.”  Thus if synthetic sperm were used 
to create the embryo through in vitro fertilization, that fact would go 
unmentioned.  If a synthetic egg were used, perhaps a third reporting 
category would be created, or the synthetic ovum might be included in 
the “donor egg” category since the birth mother would not be the genetic 
mother in either case. 
b. The Ban on Federal Funding 
Since 1996, appropriations acts have been restricted by the Dickey-
Wicker Amendment, which prohibits the National Institutes of Health 
(“NIH”) from funding research that results in the destruction of human 
embryos.50  Specifically, Dickey-Wicker bans the use of federal funds for 
the following: 
 (1) the creation of a human embryo or embryos for 
research purposes; or  
 (2) research in which a human embryo or embryos 
are destroyed, discarded, or knowingly subjected to risk 
of injury or death greater than that allowed for research 
on fetuses in utero under 45 C.F.R. 46.208(a)(2) and 42 
U.S.C. 289g(b).51 
                                                                                                             
effect of exercising supervision or control over the practice of medicine in assisted 
reproductive technology programs.”  Id. § 263a-2(i)(2). 
50 Balanced Budget Downpayment Act, I, Pub. L. No. 104-99, § 128, 110 Stat. 26, 34 
(1996).  This ban has been included annually in subsequent appropriations bills.  See, e.g., 
Consolidated Appropriations Act, 2001, Pub. L. No. 106-554, § 510(a), 114 Stat. 2763, 2763A-
71 (2000); Consolidated Appropriations Act, 2000, Pub. L. No. 106-113, § 510(a), 113 Stat. 
1501, 1501A-275 (1999); Omnibus Consolidated and Emergency Supplemental 
Appropriations Act, 1999, Pub. L. No. 105-277, § 511(a), 112 Stat. 2681, 2681-386 (1998); 
Departments of Labor, Health and Human Services, Education, and Related Agencies 
Appropriations Act, 1998, Pub. L. No. 105-78, § 513(a), 111 Stat. 1467, 1517 (1997); Omnibus 
Consolidated Appropriations Act, 1997, Pub. L. No. 104-208, § 512(a), 110 Stat. 3009, 3009-
270 (1996). 
51 Balanced Budget Downpayment Act, I § 128.  Courts have defined “the term ‘research’ 
as used in the Dickey-Wicker Amendment [as having] only one meaning, i.e., ‘a systematic 
investigation, including research development, testing and evaluation, designed to develop 
or contribute to generalizable knowledge.’”  Sherley v. Sebelius, 704 F. Supp. 2d 63, 70 
(D.D.C. 2010) (quoting 45 C.F.R. § 46.102(d) (2009)); see also 42 U.S.C. § 289g(b) (explaining 
that the risk standard is to “be the same for fetuses which are intended to be aborted and 
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The Amendment further provides that “the phrase ‘human embryo or 
embryos’ shall include any organism, not protected as a human subject 
under 45 C.F.R. 46 as of the date of enactment of this Act, that is derived 
by fertilization, parthenogenesis, cloning, or any other means from one 
or more human gametes.”52 
President Barack Obama attempted in 2009 to remove restrictions 
against federal funding for research that results in the destruction of 
human embryos.53  The Dickey-Wicker Amendment, however, arguably  
prohibits funding for such research,54 which also extends to cloning 
research.55  The Dickey-Wicker Amendment likely would require 
research on synthetic gametes joined with human gametes to be 
conducted with non-federal funds.  Thus, the impact could be similar to 
that found in the 1970s when the federal government banned the use of 
federal funds for research on in vitro fertilization:  the research 
continued with non-federal funds and in other countries, resulting in the 
birth of Louise Brown in Great Britain in 1978. 
If both synthetic sperm and synthetic ovum were used to create a 
synthetic embryo, the Dickey-Wicker Amendment would not apply.  The 
amendment defines human embryos to include any organism derived by 
“any other means from one or more human gametes,”56 but a synthetic 
embryo has no human gametes. 
c. FDA Regulation of Human Reproductive Cloning 
The FDA has effectively banned research on cloning in the United 
States since 1998.57  Somatic cell58 nuclear transfer (“SCNT”) cloning 
“entails removing the original nucleus from an egg cell and replacing 
that nucleus with one from a somatic cell, such as a skin cell.  The egg 
cell, now containing a new (for the egg cell) nucleus, is then induced to 
                                                                                                             
fetuses which are intended to be carried to term”); 45 C.F.R. § 46.204(b) (2010) (prohibiting 
research on fetuses in utero unless “the risk to the fetus is not greater than minimal and the 
purpose of the research is the development of important biomedical knowledge which 
cannot be obtained by any other means”). 
52 Balanced Budget Downpayment Act, I § 128. 
53 See Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 11, 2009). 
54 See Sherley, 704 F. Supp. 2d at 70 (granting a preliminary injunction enjoining the 
Secretary of Health and Human Services from implementing NIH guidelines allowing 
embryonic stem cell research after finding that plaintiffs were likely to succeed on the 
merits of their claim that the guidelines violated the Dickey-Wicker Amendment). 
55 JUDITH A. JOHNSON & ERIN D. WILLIAMS, CONG. RESEARCH SERV., RL 31358, HUMAN 
CLONING 7–8 (2006), available at http://www.fas.org/sgp/crs/misc/RL31358.pdf. 
56 Balanced Budget Downpayment Act, I § 128. 
57 Javitt & Hudson, supra note 10, at 1202. 
58 Somatic cells are non-reproductive cells, while germ cells are reproductive cells 
(sperm cells and egg cells).  Id. at 1214. 
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divide under laboratory conditions to form an embryo.”59  If the embryo 
is subsequently implanted in a uterus and “successfully gestated, the 
result is an organism that is a virtually identical genetic copy (with the 
exception of the mitochondrial DNA) of the source of the somatic cell.”60 
If researchers wish to perform SCNT, they must first apply to the 
FDA for an investigational new drug application.  The FDA has stated 
that it will not approve an application for such research until the safety 
concerns involved with cloning have been resolved.61 
Although a synthetic embryo might well raise safety concerns, the 
process to create one would not involve cloning.  Unlike SCNT, the 
synthetic gamete would be joined with either a human gamete or 
another synthetic gamete, so that the resulting embryo would not be an 
identical genetic copy of the synthetic material. 
The FDA also has authority to regulate the fertility drugs and 
medical devices used in ART, including “instrumentation intended for 
use in IVF and related ART procedures.”62  This could limit the research 
into synthetic genetic material only if drugs or medical devices not 
currently used in assisted reproduction are created specifically for this 
synthetic process.  This seems unlikely to occur. 
2. State Regulation of ARTs 
Although states have been more active than the federal government 
in regulating research on human embryos and fetuses, existing state laws 
would have limited impact on the creation of synthetic gametes or 
embryos.  Some states prohibit research on human embryos and 
fetuses,63 others prohibit the sale of embryos and fetuses,64 and others 
                                                 
59 Id. at 1203. 
60 Id. at 1204. 
61 Id. at 1202. 
62 Obstetric and Gynecologic Devices; Reclassification and Classification of Medical 
Devices Used for In Vitro Fertilization and Related Assisted Reproduction Procedures, 63 
Fed. Reg. 48,428, 48,428 (Sept. 10, 1998) (to be codified at 21 C.F.R. pt. 884). 
63 See, e.g., LA. REV. STAT. ANN. § 9:122 (2008) (“The use of a human ovum fertilized in 
vitro is solely for the support and contribution of the complete development of human in 
utero implantation.  No in vitro fertilized human ovum will be farmed or cultured solely 
for research purposes or any other purposes.”); ME. REV. STAT. ANN. tit. 22, § 1593(1) (2004) 
(“A person may not use, transfer, distribute or give away a live human fetus, whether 
intrauterine or extrauterine, or any product of conception considered live born, for 
scientific experimentation or for any form of experimentation.”); N.M. STAT. ANN. § 24-9A-
3(A) (LexisNexis 2007) (“No fetus shall be involved as a subject in any clinical research 
activity unless the purpose of the activity is to meet the health needs of the particular fetus 
and the fetus will be placed at risk only to the minimum extent necessary to meet such 
needs or no significant risk to the fetus is imposed by the research activity.”); see also N.M. 
STAT. ANN. § 24-9A-5(A) (outlining very limited exceptions to the general ban on “clinical 
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impose mandatory reporting requirements on IVF facilities65 or require 
IVF facilities to adhere to professional society guidelines.66  At least one 
state has set forth rules for the performance of IVF and has established 
eligibility requirements for IVF recipients.67  Louisiana goes so far as to 
identify embryos as juridical persons and prohibit their intentional 
destruction.68  In addition, as of January 2008, fifteen states regulated 
                                                                                                             
research activity involving fetuses, live-born infants or pregnant women”); R.I. GEN. LAWS 
§ 11-54-1(a) (2002) (“No person shall use any live human fetus, whether before or after 
expulsion from its mother’s womb, for scientific, laboratory research, or other kind of 
experimentation.”); S.D. CODIFIED LAWS § 34-14-17 (2004) (“No person may knowingly 
conduct nontherapeutic research that subjects a human embryo to substantial risk of injury 
or death.”). 
64 See, e.g., IND. CODE ANN. § 35-46-5-3(a) (West Supp. 2010) (“A person who knowingly 
or intentionally purchases or sells a human ovum, zygote, embryo, or fetus commits 
unlawful transfer of a human organism, a Class C felony.”); LA. REV. STAT. ANN. § 9:122 
(2008) (“The sale of a human ovum, fertilized human ovum, or human embryo is expressly 
prohibited.”); S.D. CODIFIED LAWS § 34-14-17 (2004) (“No person may sell or transfer a 
human embryo with the knowledge that the embryo will be subjected to nontherapeutic 
research.”). 
65 See 18 PA. CONS. STAT. ANN. § 3213(e) (West 2000) (“All persons conducting, or 
experimenting in, in vitro fertilization shall file quarterly reports with the department, 
which shall be available for public inspection and copying . . . .”). 
66 In Louisiana, 
 [o]nly medical facilities meeting the standards of the American 
Fertility Society and the American College of Obstetricians and 
Gynecologists and directed by a medical doctor licensed to practice 
medicine in this state and possessing specialized training and skill in 
in vitro fertilization also in conformity with the standards established 
by the American Fertility Society or the American College of 
Obstetricians and Gynecologists shall cause the in vitro fertilization of 
a human ovum to occur.  No person shall engage in in vitro 
fertilization procedures unless qualified as provided in this Section. 
LA. REV. STAT. ANN. § 9:128 (2008). 
67 In New Hampshire, 
 [i]n vitro fertilization and preembryo transfer shall be performed 
in accordance with rules adopted by the department of health and 
human services and shall be available only to a woman: 
 I. Who is 21 years of age or older; 
 II. Who has been medically evaluated and the 
results . . . demonstrate the medical acceptability of the woman to 
undergo the . . . procedure; 
 III. Who receives counseling . . . and provides written 
certification of the counseling and evaluation to the health care 
provider performing the . . . procedure; and 
 IV. Whose husband, if the recipient is married, receives 
appropriate counseling . . . and [satisfies other requirements]. 
N.H. REV. STAT. ANN. § 168-B:13 (LexisNexis 2010). 
68 In Louisiana, 
 [a] viable in vitro fertilized human ovum is a juridical person 
which shall not be intentionally destroyed by any natural or other 
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cloning in some way, either by banning the use of public funds for 
cloning or by outright prohibition of therapeutic and/or reproductive 
cloning.69  A proposed law, Georgia’s Ethical Treatment of Embryos Act, 
sought “[t]o amend Chapter 7 of Title 19 of the Official Code of Georgia 
Annotated . . . to provide that it shall be unlawful for any person or 
entity to intentionally or knowingly create or attempt to create an in vitro 
human embryo by any means other than fertilization of a human egg by 
a human sperm or intracytoplasmic sperm injection.”70  None of these 
enacted or proposed state laws would impact research on synthetic 
genetic materials as long as the creation of synthetic gametes is not 
considered “research,” and the resulting embryo is not defined as 
“human.”     
3. Professional Societies’ Recommendations on ARTs 
Professional societies would likewise have little impact on the 
research of synthetic embryos.  The American Society for Reproductive 
Medicine (“ASRM”), in conjunction with its sister organization, the 
Society for Assisted Reproductive Technology, “provides guidance by 
means of published statements, opinions, and guidelines issued by its 
practice and ethics committees.  The chief values ASRM seeks to promote 
through its opinions and guidelines are safety (of ART participants), 
efficacy (of techniques and procedures), and privacy (of ART 
patients).”71  ASRM issues both practice guidelines and ethical guidelines 
on a variety of issues related to ART.72  Because compliance is voluntary, 
however, professional guidelines are generally unenforceable.73 
                                                                                                             
juridical person or through the actions of any other such person.  An in 
vitro fertilized human ovum that fails to develop further over a thirty-
six hour period except when the embryo is in a state of 
cryopreservation, is considered non-viable and is not considered a 
juridical person. 
LA. REV. STAT. ANN. § 9:129 (2008). 
69 See Human Cloning Laws, NAT’L CONF. ST. LEGISLATURES (Jan. 2008), 
http://www.ncsl.org/default.aspx?tabid=14284.  Those fifteen states are Arizona, 
Arkansas, California, Connecticut, Indiana, Iowa, Maryland, Massachusetts, Michigan, 
Missouri, New Jersey, North Dakota, Rhode Island, South Dakota, and Virginia.  Id. 
70 S.B. 169, 150th Gen. Assemb., Reg. Sess. (Ga. 2009), available at http://www1.legis.ga. 
gov/legis/2009_10/pdf/sb169.pdf.  The Act passed the Georgia State Senate by a vote of 
34-22 on March 12, 2009, but it did not proceed to a vote within the House.  See Senate Vote 
216, GA. GEN. ASSEMB., http://www1.legis.ga.gov/legis/2009_10/votes/sv0216.htm (last 
visited Apr. 16, 2011). 
71 2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 72. 
72 See, e.g., 2008 Guidelines for Gamete and Embryo Donation:  A Practice Committee Report, 
90 FERTILITY & STERILITY S30, S30 (Nov. 2008) [hereinafter 2008 Guidelines for Gamete and 
Embryo Donation]; Ethics Committee of the American Society of Reproductive Medicine, 
Disposition of Abandoned Embryos, 82 FERTILITY & STERILITY S253 (Sept. 2004); Guidelines on 
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B. Gametes 
Although the government has occasionally asserted authority to 
regulate specific practices,74 gametes (sperm and ova) remain largely 
unregulated by both the federal government and states.75  The FDA is 
mainly concerned with keeping infectious reproductive tissue out of the 
market through regulations on screening, processing, and record 
keeping.76 
1. Federal Regulation of Gametes 
Semen and other reproductive material, including oocytes, are 
considered HCT/Ps:  Human Cells, Tissues, and Cellular and Tissue-
Based Products regulated by the FDA.77  As such, they are subject to 
rules designed to prevent communicable diseases.78  A key question is 
whether synthetic gametes should be 
regulated solely under 21 C.F.R. Part 1271, the 
regulations to prevent communicable disease 
transmission authorized by section 361 of the Public 
Health Service Act. . . . [or] as biological products, drugs, 
or devices under section 351 of the Public Health Service 
Act and/or the Food Drug and Cosmetic Act.79 
                                                                                                             
Number of Embryos Transferred, 86 FERTILITY & STERILITY S51 (2006); Preconception Gender 
Selection for Nonmedical Reasons, 75 FERTILITY & STERILITY 861 (May 2001); ; see also Michael J. 
Malinowski, Choosing the Genetic Makeup of Children:  Our Eugenics Past—Present, and 
Future?, 36 CONN. L. REV. 125, 185–87 (2003) (identifying additional professional 
guidelines). 
73 See 2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 175.  But see LA. REV. STAT. 
ANN. § 9:128 (2008) (requiring clinics to adhere to professional guidelines). 
74 See infra Part III.B.2 (discussing the FDA’s claim of regulatory authority over 
ooplasmic transfer). 
75 See infra Parts III.B.1, III.B.3 (discussing federal and state regulation of gametes). 
76 Yuen, supra note 14, at 554. 
77 Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment 
Registration and Listing, 66 Fed. Reg. 5447, 5448 (Jan. 19, 2001) (to be codified at 21 C.F.R. 
pts. 207, 807, 1271). 
78 21 C.F.R. § 1271.75 (2010).  Sections 1271.85(a)–(c) of the regulations require 
anonymously donated gametes to be tested for the following diseases:  human 
immunodeficiency virus, type 1; human immunodeficiency virus, type 2; hepatitis B virus; 
hepatitis C virus; treponema pallidum; human T-lymphotropic virus, type I; human T-
lymphotropic virus, type II; cytomegalovirus (“CMV”); chlamydia trachomatis; and 
neisseria gonorrhea.  21 C.F.R. § 1271.85(a)–(c). 
79 Letter to Sponsors/Researchers—Human Cells Used in Therapy Involving the Transfer of 
Genetic Material by Means Other Than the Union of Gamete Nuclei, U.S. FOOD & DRUG ADMIN. 
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2. FDA Regulation of Oocytes 
The FDA has asserted its jurisdiction to control research involving 
oocyte nuclear transfer and a related procedure, ooplasmic transfer.  In 
1998, researchers used oocyte nuclear transfer by 
removing the nucleus from a woman’s egg and injecting 
it into a donor’s egg, from which the nucleus had 
already been removed.  The technique was meant to 
help older women whose infertility was believed linked 
to problems with the cytoplasm of her own eggs.  The 
reconstructed egg was then fertilized with the father’s 
sperm and implanted in the patient’s womb.  (This is not 
cloning, because an adult cell is not involved, but the 
nuclear transfer process is the same.)80 
The researchers “gave their findings to doctors in China because 
regulations imposed by the [FDA] in 2001 made it too difficult to 
continue the research in the United States.”81 
Ooplasmic transfer was developed by Dr. Jacques Cohen of the Saint 
Barnabas Medical Center in New Jersey.  Rather than transferring the 
nuclei of the intended mother into the denucleated donor egg, as in 
oocyte nuclear transfer, the ooplasm (or cytoplasm) from the donor egg 
is “injected into the ooplasm of another woman whose embryos 
previously failed to develop.”82  As with oocyte nuclear transfer, a child 
born using ooplasmic transfer has genetic material from three sources:  
the donor egg, the intended mother’s egg, and the sperm.83 
In July 2001, the FDA sent a letter to the New Jersey researchers 
regarding the ooplasmic transfer which stated the following: 
                                                                                                             
(May 6, 2009), http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm 
105852.htm. 
80 HENRY C. LEE & FRANK TIRNADY, BLOOD EVIDENCE:  HOW DNA IS REVOLUTIONIZING 
THE WAY WE SOLVE CRIMES 318 (2003). 
81 Denise Grady, Pregnancy Created Using Egg Nucleus of Infertile Woman, N.Y. TIMES, Oct. 
14, 2003, at A22, http://query.nytimes.com/gst/fullpage.html?res=980DE4D7113FF937A 
25753C1A9659C8B63&pagewanted=all. 
82 Anne Drapkin Lyerly, Marking the Fine Line:  Ethics and the Regulation of Innovative 
Technologies in Human Reproduction, 11 MINN. J. L. SCI. & TECH. 685, 701 (2010).  For 
additional information on ooplasm transfer, see also, BIOLOGICAL RESPONSE MODIFIERS 
ADVISORY COMM., DEP’T OF HEALTH & HUMAN SERVS., BRIEFING DOCUMENT FOR DAY 1, 
MAY 9, 2002, OOPLASM TRANSFER AS METHOD TO TREAT FEMALE INFERTILITY, [hereinafter 
BRMAC, BRIEFING DOCUMENT], available at http://www.fda.gov/OHRMS/DOCKETS/ 
ac/02/briefing/3855B1_01.pdf. 
83 Javitt & Hudson, supra note 10, at 1226; see also LEE & TIRNADY, supra note 80, at 318. 
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We want to advise you that the Food and Drug 
Administration (FDA) has jurisdiction over human cells 
used in therapy involving the transfer of genetic 
material by means other than the union of gamete 
nuclei. 
 
Examples of such genetic material include, but are not 
limited to: 
 
• cell nuclei (e.g., for cloning), 
• oocyte nuclei, 
• ooplasm, which contains mitochondrial genetic 
material, and 
• genetic material contained in a genetic vector, 
transferred into gametes or other cells. 
 
The use of such genetically manipulated cells (and/or 
their derivatives) in humans constitutes a clinical 
investigation and requires submission of an 
Investigational New Drug application (IND) to FDA.  
We wish to inform you of the FDA regulatory process 
governing clinical investigations, which includes 
requirements applicable to manufacturing processes, the 
study of the safety and efficacy of such cells, and the 
protection of human participants in such studies.  We 
can advise you whether or not your activities require 
submission of an IND.  If what you are doing or plan to 
do does require an IND, we would be pleased to provide 
you with information and guidance regarding filing 
such an application.84 
Would a synthetic gamete constitute the “use of such genetically 
manipulated cells (and/or their derivatives) in humans”?  Arguably not.  
Synthetic sperm or ova would contain chemically created DNA, not 
human DNA, and thus would be outside of the banned procedures cited 
in the letter.  The use of a synthetic gamete avoids the problem of 
“heteroplasmy,” that is, the mixing of ooplasm, and specifically 
mitochondria, from more than one individual: 
According to the FDA, “it is clear that stringent 
mechanisms have evolved to insure homogeneity of 
                                                 
84 See Letter to Sponsors/Researchers, supra note 79. 
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mitochondrial genotypes at the initiation of human 
development.  The FDA has concerns about the safety of 
perturbing this process.”  Moreover, ooplasm transfer 
“changes the genetic makeup of the resulting offspring.  
Appropriate follow-up of children born after ooplasm 
transfer and their progeny must therefore be considered 
carefully.”85 
A broader reading of the FDA’s regulations on HCT/Ps, however, 
might apply to research on synthetic gametes.  The regulations at 21 
C.F.R. § 1271.10 include a list of requirements for Public Health Service 
Act section 361 products, including gametes and embryos, which are to 
be subject to less stringent regulation (with no FDA pre-market review) if 
the HCT/P is “minimally manipulated.”86  Combining sperm with ova 
through intracytoplasmic sperm injection (“ICSI”),87 for example, has 
fallen into this category requiring no review.  In our case, using ICSI to 
inject synthetic sperm into a human ovum could be within the reach of 
section 361; the same would be true for injecting human sperm into a 
synthetic ovum.   
Several articles have urged the FDA to expand the scope of their 
review to include assisted reproduction, especially IVF, but so far to no 
avail.88  If the FDA disagreed and chose to categorize the synthetic 
gametes under section 351 of the Public Health Service Act, then the 
research would be treated as an investigational new drug and subject to 
the same extensive testing as a new pharmaceutical.  Section 351 
products are those that do not meet the Section 1271.10 requirements and 
are regulated like drugs and/or biological products, requiring FDA pre-
market review and approval.  They represent more risk and include gene 
therapy products, human cloning, and human cells used in therapy 
involving the transfer of genetic material.  The synthetic cell could fit 
into this more regulated category, although it generally refers to somatic 
(i.e., non-gamete) cell therapies like cloning and gene therapy that 
typically involve replacing defective genes.  Still, the argument can be 
made that the stringent regulations that apply when DNA is being 
manipulated demonstrate a risk-based intent and should therefore apply 
where DNA is being manufactured. 
                                                 
85 Javitt & Hudson, supra note 10, at 1227 (footnotes omitted) (quoting BRMAC, BRIEFING 
DOCUMENT, supra note 10, at 4). 
86 21 C.F.R. § 1271.10(a)(1) (2010). 
87 Intracytoplasmic sperm injection, developed in the 1990s, involves inserting a single 
sperm into an egg and then implanting the resulting embryo. 
88 See, e.g., Baruch, supra note 42, at 262–63; King, supra note 38, at 288–89; Malinowski, 
supra note 74, at 219–20. 
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3. State Regulation of Gametes 
State legislation on gametes is concerned largely with the sale of 
sperm or eggs for valuable consideration, ensuring informed consent 
before donation, and resolving issues of property ownership of 
deposited gametes.  New York, for example, broadly prohibits the sale of 
tissue for valuable consideration.89 Other states specifically ban the sale 
of human gametes for certain purposes,90 while Florida  permits only 
“reasonable compensation” for donation.91  Some states have enacted 
laws requiring informed consent before gametes can be donated to 
research,92 and some criminalize use that is inconsistent with the gamete 
provider’s purpose.93  Finally, some states address issues of parentage94 
or the disposition of gametes in the event of death or divorce.95 
                                                 
89 N.Y. PUB. HEALTH LAW § 4364(5) (McKinney 2002) (“No bank or storage facility shall 
sell or otherwise transfer tissue for valuable consideration.  Valuable consideration shall 
not include reasonable costs associated with the procurement, processing, storage and 
distribution of tissue.”). 
90 See CAL. HEALTH & SAFETY CODE § 125350 (West Supp. 2010) (prohibiting the sale of 
human oocytes “for the purposes of medical research or development of medical 
therapies”); CONN. GEN. STAT. ANN. § 19a-32d(c)(3) (West Supp. 2010) (“A person who 
elects to donate for stem cell research purposes any . . . unfertilized human eggs or human 
sperm . . . shall not receive direct or indirect payment for such . . . unfertilized human eggs 
or human sperm.”); IND. CODE ANN. § 35-46-5-3(a) (West Supp. 2010) (criminalizing the 
purchase or sale of human ova); LA. REV. STAT. ANN. § 9:122 (2008) (prohibiting the sale of 
human ova). 
91 FLA. STAT. ANN. § 742.14 (West 2010) (“Only reasonable compensation directly related 
to the donation of eggs, sperm, and preembryos shall be permitted.”). 
92 See, e.g., CAL. HEALTH & SAFETY CODE § 125335(a) (“Prior to obtaining informed 
consent from a subject for [assisted oocyte production (“AOP”)] or any alternative method 
of ovarian retrieval on a subject for the purpose of procuring oocytes for research or the 
development of medical therapies, a physician and surgeon shall provide to the subject a 
standardized medically accurate written summary of health and consumer issues 
associated with AOP and any alternative methods of oocyte retrieval.”); CONN. GEN. STAT. 
ANN. § 19a-32d(c)(3) (“A person who elects to donate for stem cell research purposes 
any . . . unfertilized human eggs or human sperm shall provide written consent for that 
donation . . . .”). 
93 CAL. PENAL CODE 367g(a) (West 2010) (“It shall be unlawful for anyone to knowingly 
use sperm, ova, or embryos in assisted reproduction technology, for any purpose other 
than that indicated by the sperm, ova, or embryo provider’s signature on a written consent 
form.”). 
94 See, e.g., TEX. FAM. CODE ANN. § 160.706(a) (West 2008) (“If a marriage is dissolved 
before the placement of eggs, sperm, or embryos, the former spouse is not a parent of the 
resulting child unless the former spouse consented in a record . . . .”); Id. § 160.707 (“If a 
spouse dies before the placement of eggs, sperm, or embryos, the deceased spouse is not a 
parent of the resulting child unless the deceased spouse consented in a record . . . .”). 
95 FLA. STAT. ANN. § 742.17 (“A commissioning couple and the treating physician shall 
enter into a written agreement that provides for the disposition of the commissioning 
couple’s eggs, sperm, and preembryos in the event of a divorce, the death of a spouse, or 
any other unforeseen circumstance.”). 
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None of these statutes would limit creating synthetic gametes as 
long as researchers did not violate laws on informed consent or valuable 
consideration for the human gametes analyzed for their DNA sequences.  
As is the case with embryos, the professional societies’ limitations on 
buying and selling gametes are voluntary and thus would be applicable 
only in cases where a state has mandated compliance with a professional 
society’s guidelines.96  The parentage statutes, however, may apply to 
the successful use of a synthetic gamete, an issue to which we now turn. 
IV.  PARENTAGE AND INHERITANCE FOR CHILDREN WITH SYNTHETIC 
GAMETES 
Assuming that the practical and regulatory problems are resolved, 
and a child is created using synthetic gametes, who are the parents?  
Traditional notions of “genetic parents” and “birth mothers”97 may break 
down once we have the ability to create sperm or ova entirely from 
chemicals. 
The 2008 Uniform Probate Code (“UPC”) sections on assisted 
reproduction answer the parentage questions fairly easily because the 
UPC looks at intended parents rather than genetic parents.  First, 
consider three scenarios with two intended parents, both alive: 
1. Synthetic sperm and the ovum of the birth mother:  UPC 
section 2-120 declares that the birth mother is the 
child’s mother,98 as do most state statutes.  The key 
question is, who is the father?  If the birth mother is 
married, then her husband is presumed to have 
consented to be the father, a presumption that can 
be rebutted by clear and convincing evidence.99  If 
the birth mother is not married, then consent to 
assisted reproduction with the intent to be the 
parent of the resulting child can be shown by a 
signed record or functioning as a parent no later 
than two years after the child’s birth.100 
                                                 
96 2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 178; see, e.g., 2008 Guidelines for 
Gamete and Embryo Donation, supra note 72, at S30. 
97 “Birth mother” is defined as “a woman, other than a gestational carrier under Section 
2-121, who gives birth to a child of assisted reproduction.  The term is not limited to a 
woman who is the child’s genetic mother.”  UNIF. PROBATE CODE § 2-120(a)(1) (amended 
2008), 8 U.L.A. 58 (Supp. 2010). 
98 Id. § 2-120(c). 
99 Id. § 2-120(h)(1). 
100 Id. § 2-120(f)(1), (f)(2)(A). 
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2. Synthetic sperm and donated human ovum where the 
intended mother gives birth:  The UPC treats this 
scenario the same as the first, because the UPC looks 
at the intended parents rather than the genetic 
parents.  The ovum donor is not a parent, so she is 
out of the equation.101  A parent-child relationship 
exists with the birth mother and may exist with the 
birth mother’s husband or partner as in scenario 
one.  The problem is the existing statutes in many 
states that have not been updated to include ova 
donations.  Some states have statutes modeled after 
the 1973 Parentage Act that stipulate that a donor 
who gives sperm to a licensed physician for use by a 
married woman is not the father of the resulting 
child.102  In one of these states, the ovum “donor” 
might still be able to claim she is the child’s mother 
because her donation did not comply with the 
statutory language.103 
 
3. Human sperm and synthetic ovum where the intended 
mother gives birth:  There are no complications here.  
The birth mother is presumed to have a parent-child 
relationship, which is what the parties intend.  For 
the father, if he is married to the birth mother, he is 
the father because his sperm was used during his 
lifetime,104 so long as the couple did not divorce 
before placement (implantation) of the sperm, eggs, 
or embryos, and he did not withdraw his consent, in 
writing, before the placement.105  If the birth mother 
is single, the other intended parent must show his 
consent through the means detailed in scenario one. 
                                                 
101 Id. § 2-120(b). 
102 See, e.g., MINN. STAT. ANN. § 257.56(2) (West 2007); MO. ANN. STAT. § 210.824 (West 
2010); MONT. CODE ANN. § 40-6-106 (2009); NEV. REV. STAT. ANN. § 126.061 (LexisNexis 
2010); WISC. STAT. ANN. § 891.40 (West 1997 & Supp. 2010). 
103 See, e.g., Jhordan C. v. Mary K., 179 Cal. App. 3d 386, 393 (1986) (noting that the 
California statute is limited “to instances in which the semen is provided to a licensed 
physician.... Accordingly, [the California statute] by its terms does not apply to the present 
case” in which sperm was provided directly to the woman, and thus the sperm “donor” 
was the legal father).  Accord, Turchyn v. Cornelius, 1999 Ohio App. LEXIS 4129 (1999). 
104 UNIF. PROBATE CODE § 2-120(d). 
105 Id. § 2-120(i), (j). 
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The next scenario involves the use of a gestational carrier and so the 
intended mother is not the birth mother.  Under the UPC, the gestational 
carrier is not a parent of the resulting child unless a court so orders, or in 
cases where the gestational carrier is the genetic mother and no one else 
has a parent-child relationship.106 
4. Gestational carrier is birth mother with synthetic sperm 
and/or ovum:  Because of cases such as In re Baby 
M,107 gestational carriers are rarely genetically 
related to the child; either the intended mother’s 
ovum or a donated ovum is implanted.  In several 
states, the birth mother is conclusively presumed to 
be the child’s mother, which is not what the parties 
intend.  Statutes in two states that conclusively 
presumed the gestational carrier to be the child’s 
mother have been struck down as 
unconstitutional.108  If the gestational carrier is not 
the mother, then the UPC would treat the intended 
parents as the legal parents of the child, as in our 
previous scenarios. 
Finally, we must consider the parentage issues if either the 
implantation of the embryo containing a synthetic gamete, or the 
gestational agreement concerning such an embryo, has occurred after 
one or both of the intended parents has died, commonly called 
postmortem conception (“PMC”). 
PMC is the subject of numerous court cases, statutes, and newspaper 
articles.  Courts in at least nine jurisdictions have adjudicated cases 
                                                 
106 Id. § 2-121(c). 
107 In re Baby M., 537 A. 2d 1227 (1988) (surrogate Mary Beth Whitehead was also the 
genetic mother, Id. at 1234;  New Jersey Supreme Court declared surrogate was the mother 
of the resulting child, Id. at 1234).  C.f. Johnson v. Calvert, 851 P. 2d 776 (Cal. 1993) 
(surrogate was not the child’s genetic mother, Id. at  778; court noted that “although the 
[Uniform Parentage] Act recognizes both genetic consanguinity and giving birth as means 
of establishing a mother and child relationship, when the two means do not coincide in one 
woman, she who intended to procreate the child--that is, she who intended to bring about 
the birth of a child that she intended to raise as her own--is the natural mother under 
California law.  Id. at 782. 
108 See J.R. v. Utah, 261 F. Supp. 2d 1268, 1289 (D. Utah 2002); Soos v. Superior Court of 
the State of Ariz., 897 P.2d 1356, 1361 (Ariz. Ct. App. 1994) (holding that the surrogate 
statute violated the Equal Protection Clause).  In a third state, the court avoided the 
constitutional problem by extending its paternity statute to allow a gestational carrier to 
deny maternity.  In re Roberto d.B., 923 A.2d 115, 124 (Md. 2007).  
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involving PMC children.109  Several states have enacted statutes 
requiring written consent to be a parent of a PMC child;110 two states 
have statutes that eliminate some or all claims of a PMC child.111  If the 
decedent’s gametic material is used to conceive the child, the usual 
issues of parentage and inheritance of a PMC child will come into play.  
The added complexity here occurs when the decedent is not the genetic 
parent.  The consent issues can be analogized to a decedent’s consent for 
assisted reproduction in which donated gametes are used, because in 
either case, synthetic gamete or donated gamete, the decedent has no 
biological tie to the child.  The UPC provides that, in cases where no 
gestational carrier is used, the decedent’s intent to be a parent can be 
shown by a signed record or by clear and convincing evidence of such 
intent.112  If the birth mother is the decedent’s surviving spouse and no 
divorce proceedings were pending at the time of the decedent’s death, 
then the decedent is presumed to have consented to be a parent of the 
PMC child.113  However, if a gestational carrier is used, UPC section 2-
                                                 
109 Courts in New Jersey, Massachusetts, Arizona, and New York have held that state law 
allows a decedent to be named the parent of a PMC child if certain conditions are met.  See 
Gillett-Netting v. Barnhart, 371 F.3d 593, 599 (9th Cir. 2004); Woodward v. Comm’r of Soc. 
Sec., 760 N.E.2d 257, 272 (Mass. 2002); In re Estate of Kolacy, 753 A.2d 1257, 1263-64 (N.J. 
Super. Ct. Ch. Div. 2000); In re Martin B., 841 N.Y.S. 2d 207, 211 (N.Y. Sur. Ct. 2007).  Courts 
interpreting the state law of California,  Arkansas, New Hampshire  California and Virginia 
have held that a PMC child cannot inherit from a decedent.  Vernoff v. Astrue, 568 F.3d 
1102, 1112 (9th Cir. 2009); Finley v. Astrue, 270 S.W.3d 849, 850 (Ark. 2008); Khabbaz v. 
Comm’r of Soc. Sec., 930 A.2d 1180, 1182 (N.H. 2007); Schafer v. Astrue, 2011 U.S. App. 
LEXIS 7456 at 9 (4th Cir. 2011).  Florida law states that a PMC child inherits only if 
provided for in the decedent’s will, and one court has ruled that absent such testamentary 
provision a PMC child cannot inherit in intestacy and thus is ineligible for Social Security 
survivor benefits.  Stephen v. Comm’r of Soc. Sec., 386 F. Supp. 2d 1257, 1265 (M.D. Fla. 
2005); c.f. Capato v. Comm’r of Soc. Sec., 631 F.3d 626, 632 (3rd Cir. 2011) (PMC child who 
is undisputed biological child of decedent is his child for purposes of Social Security Act, 
notwithstanding Florida law). 
110 See ALA. CODE § 26-17-707 (LexisNexis 2009); CAL. PROB. CODE § 249.5 (West Supp. 
2011); COLO. REV. STAT. ANN. § 19-4-106(8) (West 2005 & Supp. 2010); DEL. CODE ANN. tit. 
13, § 8-707 (2009); FLA. STAT. ANN. § 742.17(4) (West 2010); LA. REV. STAT. ANN. § 9:391.1(A) 
(2008); N.M. STAT. ANN. § 40-11A-707 (LexisNexis Supp. 2010); N.D. CENT. CODE § 14-20-65 
(2009); TEX. FAM. CODE ANN. § 160.707 (West 2008); UTAH CODE ANN. § 78B-15-707 
(LexisNexis 2008); WASH. REV. CODE ANN. § 26.26.730 (West 2005); WYO. STAT. ANN. § 14-2-
907 (2009). 
111 See N.Y. EST. POWERS & TRUSTS LAW § 5-3.2(b) (McKinney 1999 & Supp. 2011) (noting 
that a PMC child has no claim as a pretermitted heir, but may take in other circumstances); 
VA. CODE ANN. § 20-164 (2008) (stating that any child born more than ten months after the 
death of a parent is not recognized as the child of that parent and thus cannot inherit in 
intestacy or by will). 
112 UNIF. PROBATE CODE § 2-120(f). 
113 Id. § 2-120(h)(2). 
Knapland: Synthetic Cells, Synthetic Life, and Inheritance
Produced by The Berkeley Electronic Press, 2011
1384 VALPARAISO UNIVERSITY LAW REVIEW [Vol. 45 
121 requires that the decedent’s sperm or eggs be used, and thus the 
decedent would not be a parent of the PMC child.  114 
The UPC, if enacted, would resolve the question of parenthood in 
favor of the intended parents, but to date only two states have enacted 
the UPC section on assisted reproduction.115  Many states have not 
updated their statutes to address the donation of ova; others refuse to 
enforce gestational carrier agreements.  In these states, the lack of a 
genetic parent due to the use of synthetic gametes may create problems 
for courts.  Similarly, these states may declare the gestational carrier to 
be the mother of the child regardless of her genetic connection to the 
child. 
V.  CONCLUSION 
In a paper published in 1971, seven years before he and a colleague 
successfully used in vitro fertilization for the first time to create a human 
child, Dr. Edwards warned of the possibility of the rise of gestational 
surrogacy, egg banks, gene splicing, sexing blastocysts, and artificial 
wombs.116  We have yet to address all of Dr. Edwards’ concerns over 
thirty years after Louise Brown was born in 1978.  Now that Venter’s 
announcement has opened the door to synthetic gametes, it is time to 
start thinking about both regulatory issues and parentage issues for 
synthetic sperm, ova, and embryos.  Should existing regulations of 
gametes and embryos be updated to include those created chemically?  
We have at least three choices:  we can allow researchers to proceed in 
the same manner as PGD and other techniques used in assisted 
reproduction with little regulation or oversight; we can analogize to 
oocyte transfer or cloning and stop all research until the safety issues 
have been resolved; or we can allow research with more oversight. 
                                                 
114 By the time we have successfully manufactured synthetic gametes, we may have also 
perfected an artificial womb and as a result have no need for a gestational carrier.  See 
Gretchen Reynolds, Artificial Wombs:  Will We Grow Babies Outside Their Mothers’ Bodies?, 
POPULAR SCI. (Aug. 1, 2005, 2:00 pm), http://www.popsci.com/scitech/article/2005-
08/artificial-wombs (quoting Hung-Ching Liu, the director of the Reproductive Endocrine 
Laboratory at the Center for Reproductive Medicine and Infertility at Cornell University, 
who said that an artificial human womb may be available in “‘10 years, maybe, or a little 
more . . . .  It could take as much as 50 years, but I’m very hopeful that this is possible.’”). 
115 Uniform Probate Code § 2-120 (child conceived by assisted reproduction other than 
child born to gestational carrier) has been adopted in three states:  Colorado, Minnesota 
and North Dakota.  COLO. REV. STAT. 15-11-120; MINN. STAT. ANN. 524.2-120 (Subd. 7); N.D. 
CENT. CODE 30.1-04-19.  Uniform Probate Code § 2-121 (child born to gestational carrier) 
has been adopted in Colorado and North Dakota.  COLO. REV. STAT. 15-11-121; N.D. CENT. 
CODE 30.1-04-20. 
116 Robert G. Edwards & David J. Sharpe, Social Values and Research in Human Embryology, 
231 NATURE 87, 87–91 (1971). 
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Choosing the first path may bring technologies into the marketplace 
before they are fully tested.117  If we choose the second path, it is difficult 
to foresee how the safety concerns will be addressed.  The traditional 
way is to do research on animals, but experience has shown us that 
humans do not react in precisely the same way as animals, and the 
outcomes can be unpredictable.118  Scholarly discussion urging more 
regulation and oversight of ART could be applied to the issue of 
synthetic gametes to determine the appropriate level of oversight.119 
There is a second critical issue:  once a synthetic gamete has been 
created and used to create a living child, who are the child’s parents?  
Should we move to a regime of intended parents for synthetic 
reproduction, as the UPC has already urged for children of assisted 
reproduction?  Such a move would require a fundamental shift in the 
way states approach parentage, away from biological and genetic 
markers and toward intent (or consent) to be a parent of the resulting 
child.  For reasons of public policy, consent to be a parent is presumed 
when one engages in coitus.  Even if the child was conceived under 
criminal or fraudulent circumstances (for example, a false promise of 
infertility), the progenitors are still the parents of the resulting child. 
In contrast, when a child is conceived using assisted reproduction, 
the public policy considerations are quite different, and consent (or 
                                                 
117 See, e.g., Anne Adams Lang, Doctors Are Second-Guessing The ‘Miracle’ of Multiple Births, 
N.Y. TIMES, June 13, 1999, www.nytimes.com/1999/06/13/health/doctors-are-second-
guessing-the-miracle-of-multiple-births.html?src=pm (noting that the incidence of multiple 
births has quadrupled since the mid-1980s, largely because of the use of ART, and that 
almost all are born premature with various physical problems and a highly increased 
mortality rate); Peres, supra note 32, at C1 (describing lawsuit against a medical center that 
claimed it could screen a woman’s eggs for the genes that carry cystic fibrosis using PGD 
where the resulting child had cystic fibrosis); Gladys B. White, A Devil’s Bargain for the 
Infertile:  Fertility Treatments Are Causing More Multiple Births, Leading To Risks to Mothers and 
Newborns, CHI. TRIB., June 24, 2007, at C9 (stating the same). 
118 See, e.g., Daniel G. Hackam & Donald A. Redelmeier, Translation of Research Evidence 
From Animals to Humans, 296 J. AM. MED. ASS’N 1731, 1732 (2006) (“Only about a third of 
highly cited animal research translated at the level of human randomized trials.”).  Trisha 
Gura states that 
many thousands of drugs have shown activity in either cell or animal 
models, but only 39 that are used exclusively for chemotherapy, as 
opposed to supportive care, have won approval from the U.S. Food 
and Drug Administration.  “The fundamental problem in drug 
discovery for cancer is that the model systems are not predictive at 
all.” 
Trisha Gura, Systems for Identifying New Drugs Are Often Faulty, 278 SCI. 1041, 1041 (1997) 
(quoting Alan Oliff, the former executive director for cancer research at Merck Research 
Laboratories). 
119 See, e.g., Baruch, supra note 42, at 267–70; King, supra note 38, at 288–89; Malinowski, 
supra note 72, at 197–222. 
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rather, intent) to be the parent needs to be established.  In many instances 
involving assisted reproduction, the biological parent does not intend to 
be the parent of the child.  Whenever donor sperm, ova, or embryos are 
used in assisted reproduction, the donor has usually agreed not to seek 
parentage rights in a resulting child.  Similarly, with gestational carrier 
agreements, while the carrier is biologically connected to the child as the 
birth mother, she has usually agreed she will not claim to be the 
resulting child’s mother (although her agreement may not be enforceable 
in all states).  In addressing assisted reproduction with donor gametes or 
gestational carriers, the UPC attempts to determine the parents where 
too many possibilities abound; one California case identified six different 
possible parents of the resulting child.120  With synthetic gametes, the 
problem may instead be too few possible human parents because at least 
one genetic parent will be out of the equation. 
The two UPC sections on assisted reproduction have been adopted 
in only two states despite being promulgated in 2008.121  Although some 
states may have hesitated because they do not enforce gestational carrier 
arrangements, this does not explain why they have failed to address the 
use of assisted reproduction in other ways, such as with donor gametes.  
As we move toward the possibility of synthetic gametes, the debate over 
genetic and biological parents versus intended parents will demand 
resolution. 
                                                 
120 Buzzanca v. Buzzanca, 72 Cal. Rptr. 2d. 280, 282-88 (gestational carrier and her 
husband, egg donor, sperm donor, and the genetically unrelated intended parents) (Cal. Ct. 
App. 1998). 
121  Supra note 115. 
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